Enliven Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 46
- Market Cap
- $1B
- Introduction
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headqu...
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN
ELVN-001 Phase 1 trial shows 44% cumulative MMR rate by 24 weeks in heavily pretreated CML patients, with stable or deepening responses and well-tolerated safety profile.
Related Clinical Trials:
© Copyright 2024. All Rights Reserved by MedPath